Microbot Medical Inc.

Founded in 2010 and headquartered in Hingham, Massachusetts, Microbot Medical develops robotic systems designed to improve the safety and precision of endovascular procedures. The company's primary product is LIBERTY, an endovascular robotic surgical system that enables physicians to conduct catheter-based procedures remotely from outside the catheterization laboratory. This approach aims to reduce radiation exposure, physical strain, and cross-contamination risk for clinicians performing cardiovascular, peripheral, endovascular, and neurovascular interventions. The company also holds intellectual property in NovaCross, a technology focused on intraluminal revascularization devices with integrated anchoring mechanisms and microcatheter capabilities.

Microbot Medical operates with a small team of approximately 20 full-time employees. The company has established collaborative relationships with clinical and research institutions, including a development agreement with Corewell Health for the LIBERTY system and a partnership with Emory University focused on autonomous robotics applications in endovascular procedures. These partnerships support the company's product development and clinical validation efforts within the minimally invasive surgical space.